Lantern Pharma CEO Panna Sharma joined Steve Darling from Proactive to discuss the company’s latest clinical milestone and its broader mission to transform oncology drug development through the use of artificial intelligence, machine learning, and genomic data. Lantern’s proprietary RADR® AI platform integrates billions of biological and clinical data points to identify predictive biomarkers, forecast drug response, and design more targeted and efficient clinical trials aimed at delivering precision cancer therapies to patients. The company announced additional details from its recently completed Phase 1a dose-escalation study of LP-184, its lead drug candidate. The trial produced encouraging results, demonstrating durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which exhibited deficiencies in DNA damage repair pathways—an area where LP-184 is designed to be particularly effective. Sharma told Proactive that the Phase 1a study successfully met all primary endpoints for safety and tolerability, while also clearly establishing a recommended Phase 2 dose (RP2D). He emphasized that these outcomes validate both the scientific rationale behind LP-184 and the predictive capabilities of Lantern’s AI-driven development approach. Building on these positive results, Lantern Pharma is now advancing an ambitious precision oncology strategy that includes multiple biomarker-guided Phase 1b/2 clinical trials. These studies will target major cancer indications such as triple-negative breast cancer (TNBC), glioblastoma multiforme (GBM), non-small cell lung cancer, and advanced bladder cancer. The commercial potential for LP-184 is significant. Lantern and independent industry analysts estimate that the aggregate annual market opportunity for the drug across these and additional targeted indications could exceed $10 billion. Preclinical models have shown nanomolar potency, while early clinical data indicate encouraging durability of response even in heavily pre-treated patient populations. LP-184 has also received important regulatory recognition from the U.S. Food and Drug Administration, including Fast Track Designation for TNBC and GBM, as well as Orphan Drug Designation for malignant gliomas, pancreatic cancer, and atypical teratoid/rhabdoid tumors (ATRT). Sharma noted that these designations support an accelerated development pathway as Lantern continues to move LP-184 toward later-stage clinical trials. #proactiveinvestors #laternpharma #nasdaq #ltrn #LanternPharma #PannaSharma #PrecisionOncology #CancerResearch #AIinHealthcare #MachineLearning #Genomics #ClinicalTrials #BiotechNews #OncologyInnovation #LP184 #Phase1a #Phase2Trials #BiomarkerDriven #TripleNegativeBreastCancer #Glioblastoma #LungCancer #BladderCancer #OrphanDrug #FastTrackDesignation #FDA #PrecisionMedicine
